-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades CureVac to Neutral, Lowers Price Target to $5.5

Benzinga·06/26/2025 15:26:53
Listen to the news
UBS analyst Eliana Merle downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and lowers the price target from $12 to $5.5.